
TransMedics Group, Inc.
- Jurisdiction
United States - ISIN
US89377M1099 (TMDX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
-
€66.71 51.3% overvalued - Financial strength (Piotroski F-Value)
-
8
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€453.17M - Gross margin
59.8% - EBIT
€65.32M - EBIT margin
14.4% - Net income
€61.12M - Net margin
13.5%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Hassanein Waleed H | President & CEO |
|
|
|
|
Basile Edward M | N/A |
|
|
|
|
Earnings Calls
Investor transactions
Name | Shares | Value | Last change | Change type |
---|---|---|---|---|
James Anderson |
|
|
|
Sell |
Earnings Calls
Latest earnings call: April 30, 2024 (Q1 2024)